ChromaCode
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 2.9m | 4.0m | 6.6m | 28.2m | 28.2m | 28.2m |
% growth | - | 38 % | 66 % | 326 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$12.0m | Series B | ||
* | $28.0m | Series C | |
* | $10.0m | Series C | |
$6.0m | Grant | ||
* | N/A | Late VC | |
Total Funding | $56.0m |
Recent News about ChromaCode
EditChromaCode is a pioneering molecular diagnostics company that is revolutionizing precision diagnostics through advanced multiplexing technology. The company serves clinical laboratories and healthcare providers, operating within the molecular diagnostics market. ChromaCode's core product, HDPCR technology, significantly expands the number of detectable disease targets in a single reaction, up to four times more than traditional methods. This is achieved without requiring changes to existing qPCR or dPCR instruments, making it a cost-effective solution for labs. The business model revolves around selling enhanced PCR reagents and cloud-based software, generating revenue through the sale of these products and associated services. By leveraging digital signal processing, ChromaCode enables broader coverage and more rapid disease identification, ultimately reducing costs and increasing efficiency for its clients.
Keywords: molecular diagnostics, multiplexing, HDPCR, qPCR, dPCR, disease detection, healthcare, precision diagnostics, cloud software, cost-effective.